Clinical Trial Update: Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study investigating Antiminor Histocompatibility Complex (MiHA) T cells in patients with relapsed hematologic malignancies after matched hematopoietic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Hodgkin Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma

Drugs mentioned

• Antiminor Histocompatibility Complex (MiHA) T Cells (MiHA T cells)

Snippet

Sponsor: Ciusss de L'Est de l'Île de Montréal | Conditions: Hematologic Cancer, Relapse Leukemia | Phase 1, Phase 2 | Status: UNKNOWN